Tenosynovial giant cell tumor (TGCT) is typically a non-malignant neoplasm that can be locally aggressive1
While TGCT may be non-malignant, it is still a chronic and debilitating disease that may lead to life-altering joint damage and disability2,3


Estimated recurrence rates after resection
Incidence and prevalence of TGCT
It is unknown how many people are currently living with this rare disease, but worldwide estimates were extrapolated from a study in the Netherlands.6
in a knee joint

Localized (GCT-TS)
Estimated 39 cases
per million person-years
~13,000 patients in the
United States in 20196,7
80%-90%
OF TGCT CASES4
DIFFUSE (PVNS)
Estimated 4 cases
per million person-years
~1300 patients in the
United States in 20196,7
10%-20%
OF TGCT CASES4

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) recommend that—prior to the initiation of therapy—all patients be evaluated and managed by a multidisciplinary team with expertise and experience in sarcoma8
Complete resection should be considered but isn't always an option
Surgical outcomes depend on many factors, including localization and extent of the disease and patient characteristics1,4,9
Recurrence rates after surgery in diffuse TGCT have been seen as high as4
Diffuse TGCT may lead to invasive surgical resection and deteriorating quality of life due to recurrence1
Many patients may
require multiple surgeries.
This can lead to6,10,11:

function of the
affected joints6,11,12

replacement or
amputation6,10

of infection6

complications11,12
Because of the locally aggressive and recurrent nature of TGCT, which may lead to functional limitations and a severe decline
in quality of life, multiple surgeries may be required.2,5,6
PATIENT ID PAGE